Verastem Company Profile (NASDAQ:VSTM)

About Verastem

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VSTM
  • CUSIP: 92337C10
Key Metrics:
  • Previous Close: $1.18
  • 50 Day Moving Average: $1.22
  • 200 Day Moving Average: $1.26
  • 52-Week Range: $1.05 - $1.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.06
  • P/E Growth: -0.59
  • Market Cap: $42.91M
  • Outstanding Shares: 36,992,000
Additional Links:
Companies Related to Verastem:

Analyst Ratings

Consensus Ratings for Verastem (NASDAQ:VSTM) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $3.17 (168.36% upside)

Analysts' Ratings History for Verastem (NASDAQ:VSTM)
DateFirmActionRatingPrice TargetDetails
1/10/2017Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details
11/12/2016HC WainwrightReiterated RatingBuyView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingHold$1.50View Rating Details
11/11/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformView Rating Details
9/29/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
9/29/2015Raymond James Financial, Inc.DowngradeStrong-Buy -> Outperform$12.00 -> $3.00View Rating Details
9/28/2015MizuhoDowngradeBuy -> Neutral$21.00 -> $2.00View Rating Details
9/28/2015Roth CapitalDowngradeBuy -> Neutral$23.00 -> $2.00View Rating Details
(Data available from 2/28/2015 forward)


Earnings History for Verastem (NASDAQ:VSTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017($0.26)N/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Verastem (NASDAQ:VSTM)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-1.11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20161($0.33)($0.33)($0.33)
Q3 20162($0.26)($0.24)($0.25)
Q4 20162($0.28)($0.22)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Verastem (NASDAQ:VSTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Verastem (NASDAQ:VSTM)
News IconWhat is the Sell-side Saying About Verastem, Inc. (NASDAQ:VSTM)? - Aiken Advocate (NASDAQ:VSTM) - February 27 at 5:24 PM
News IconVerastem Inc VSTM Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:VSTM) - February 22 at 11:11 AM
News IconSell-side is Weighing in on Verastem, Inc. (NASDAQ:VSTM) Earnings - Aiken Advocate (NASDAQ:VSTM) - February 21 at 8:15 AM
News IconVerastem, Inc. (NASDAQ:VSTM) Quarterly EPS Projection At $-0.27 - Stock Observer (NASDAQ:VSTM) - February 12 at 6:37 AM
News IconVerastem Inc VSTM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:VSTM) - February 9 at 6:35 AM
News IconVolatility Spiking as Shares Ride the Wave: Verastem, Inc. (NASDAQ:VSTM) - Davidson Register (NASDAQ:VSTM) - February 7 at 3:38 PM logoVerastem to Present at 19th Annual BIO CEO & Investor Conference (NASDAQ:VSTM) - February 7 at 3:38 PM
News IconOn the Hunt For the Next Wonder Stock: Penny Stock Verastem, Inc. (NASDAQ:VSTM) - Nelson Research (NASDAQ:VSTM) - February 2 at 6:39 AM
News IconInvestor Box: Viewing Levels on Shares of Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - February 2 at 6:39 AM
News IconIs This Stock Capable of a Bull Run: Verastem, Inc. (NASDAQ:VSTM) - Nelson Research (NASDAQ:VSTM) - January 30 at 4:15 PM
News IconInvestor Focus on Technical Levels for Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - January 30 at 4:15 PM
News IconAnalysts Take: Verastem, Inc. (NASDAQ:VSTM) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:VSTM) - January 30 at 4:15 PM
News IconIs Verastem Inc (VSTM)’s Fuel Running Low? The Stock Formed Multiple Bottom (NASDAQ:VSTM) - January 30 at 9:59 AM
News IconStock Spotter: Review on Technical Levels for Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - January 27 at 3:49 PM
News IconMeasuring the Levels on Shares of Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - January 27 at 3:49 PM
News IconRipe for A Big Move? Update on Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - January 27 at 3:49 PM logoVerastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer (NASDAQ:VSTM) - January 27 at 6:41 AM logoInfinity Pharma Surges On Latest Cancer Drug Hope (NASDAQ:VSTM) - January 25 at 4:25 PM
News IconUnusual Activity Unfolding Mid-Session For Verastem, Inc. (NASDAQ:VSTM) - Aiken Advocate (NASDAQ:VSTM) - January 25 at 1:28 AM
News IconEquity Rundown: RSI and CCI Check on Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - January 24 at 3:24 PM
News IconEarnings in Full Force, Analysts Take Aim at Verastem, Inc. (NASDAQ:VSTM) - Wall Street Beacon (NASDAQ:VSTM) - January 24 at 3:24 PM
News IconTrading Radar: Checking Technicals for Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - January 24 at 2:27 AM
News IconStock Update: Estimates & Target in Focus for Verastem, Inc. (NASDAQ:VSTM) - Aiken Advocate (NASDAQ:VSTM) - January 24 at 2:27 AM
News IconReady for an Upsurge? Analysts Chime in on Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - January 24 at 2:27 AM
News IconVerastem Release: Company Announces Executive Leadership Appointments And Changes (NASDAQ:VSTM) - January 21 at 1:38 AM
News IconAmplified Volatility Spotted in Shares of Verastem, Inc. (NASDAQ:VSTM) - Wall Street Beacon (NASDAQ:VSTM) - January 20 at 8:37 PM logoVerastem Announces Executive Leadership Appointments and ... - Yahoo Finance (NASDAQ:VSTM) - January 20 at 3:35 PM
News IconTaking Aim at Shares of Verastem, Inc. (NASDAQ:VSTM) | Prospect ... - Prospect Journal (NASDAQ:VSTM) - January 20 at 3:35 PM logoVerastem Announces Executive Leadership Appointments and ... - Business Wire (press release) (NASDAQ:VSTM) - January 20 at 6:03 AM logoVerastem Announces Executive Leadership Appointments and Changes (NASDAQ:VSTM) - January 19 at 9:03 PM logo4:30 pm Verastem appoints Hagop Youssoufian as Head of Hematology and Oncology Development (NASDAQ:VSTM) - January 19 at 9:03 PM logoVerastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors - Benzinga (NASDAQ:VSTM) - January 19 at 4:01 PM
News IconRating Sentiment Reporting: Is there a Bearish outlook for Verastem Inc (NASDAQ:VSTM) this week? - Fair View Times (NASDAQ:VSTM) - January 19 at 4:01 PM logoVerastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors (NASDAQ:VSTM) - January 19 at 4:01 PM
News IconStock to Watch: Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - January 18 at 3:46 PM
News IconTracking CCI Levels on Shares of Verastem Inc. (VSTM) - Sherwood Daily (NASDAQ:VSTM) - January 17 at 3:49 PM
News IconWill The Needle Move For Verastem, Inc. (NASDAQ:VSTM) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:VSTM) - January 17 at 3:49 PM
News IconLooking Ahead for Verastem, Inc. (NASDAQ:VSTM); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:VSTM) - January 16 at 12:22 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Verastem, Inc. (NASDAQ:VSTM) - Wall Street Beacon (NASDAQ:VSTM) - January 15 at 3:45 AM
News IconEPS Of Verastem, Inc. (NASDAQ:VSTM) At $-0.27 - Stock Observer (NASDAQ:VSTM) - January 15 at 3:45 AM
News IconNews Impact Score Of Verastem, Inc. (NASDAQ:VSTM) Set At 92 - Stock Observer (NASDAQ:VSTM) - January 13 at 5:45 AM
News IconIs This a Sensible Stock at Current Levels: Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - January 13 at 5:45 AM
News IconCan This Stock Gain Any Traction: Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - January 11 at 8:32 PM logoVERASTEM, INC. Files SEC form 8-K/A, Other Events (NASDAQ:VSTM) - January 11 at 8:32 PM
News IconVerastem, Inc. (NASDAQ:VSTM) EPS At $-0.27 - Stock Observer (NASDAQ:VSTM) - January 8 at 6:35 AM
News IconBargain Hunter Investor Update on Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - January 7 at 6:24 AM
News IconAre There Catalysts to Propel This Stock Forward: Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - January 2 at 3:39 PM
News IconVerastem, Inc. (NASDAQ:VSTM) News Impact Score At 92 - Stock Observer (NASDAQ:VSTM) - December 30 at 9:03 AM
News IconStreetwise Investors Taking Note of Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - December 30 at 9:02 AM
News IconAre These Shares a Bargain: Update on Verastem, Inc. (NASDAQ:VSTM) - Prospect Journal (NASDAQ:VSTM) - December 28 at 8:18 AM


What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Where is Verastem's stock going? Where will Verastem's stock price be in 2017?

3 brokers have issued 1 year price objectives for Verastem's shares. Their predictions range from $1.50 to $5.00. On average, they expect Verastem's stock price to reach $3.17 in the next twelve months.

When will Verastem announce their earnings?

Verastem is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Verastem stock?

Verastem's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.76%) and FMR LLC (2.44%). Company insiders that own Verastem stock include Dan Paterson, Michael Kauffman, Monica Singh and Robert Forrester.

Who bought Verastem stock? Who is buying Verastem stock?

Verastem's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC and Renaissance Technologies LLC. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Monica Singh and Robert Forrester.

How do I buy Verastem stock?

Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Verastem stock cost?

One share of Verastem stock can currently be purchased for approximately $1.18.

Verastem (NASDAQ:VSTM) Chart for Tuesday, February, 28, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)

Earnings History Chart

Earnings by Quarter for Verastem (NASDAQ:VSTM)

Dividend History Chart

Dividend Payments by Quarter for Verastem (NASDAQ:VSTM)

Last Updated on 2/28/2017 by Staff